Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Accumulated Expenses (2020 - 2025)

SOPHiA GENETICS's Accumulated Expenses history spans 6 years, with the latest figure at $20.7 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 56.89% to $20.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.7 million, a 56.89% increase, with the full-year FY2025 number at $20.7 million, up 56.89% from a year prior.
  • Accumulated Expenses hit $20.7 million in Q4 2025 for SOPHiA GENETICS, up from $16.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for SOPH hit a ceiling of $20.7 million in Q4 2025 and a floor of $10.5 million in Q1 2023.
  • Historically, Accumulated Expenses has averaged $14.2 million across 5 years, with a median of $13.8 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: soared 75.88% in 2021 and later crashed 31.63% in 2023.
  • Tracing SOPH's Accumulated Expenses over 5 years: stood at $16.0 million in 2021, then decreased by 9.18% to $14.5 million in 2022, then increased by 22.77% to $17.8 million in 2023, then decreased by 25.78% to $13.2 million in 2024, then surged by 56.89% to $20.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for SOPH at $20.7 million in Q4 2025, $16.7 million in Q3 2025, and $13.7 million in Q2 2025.